ESG Engagement Register

ESG Engagement Register

Q2 2021

Royal Bafokeng Platinum

Engagement with the Chairman and Lead Independent regarding general ESG matters

Q2 2021

Naspers/Prosus

Sent a collaborative investor engagement letter to PRX, NPN Boards regarding concerns associated with the Prosus voluntary share exchange offer for Naspers shares

Q2 2021

MTN

Engagement with the Chairman of the Board where ESG matters were addressed

Q2 2021

Firstrand

Engagement with Firstrand’s sustainability team regarding their approach to Climate Change

Q2 2021

Nedbank

Engaged with the Chairman during their annual ESG roadshow

Q2 2021

Standard Bank

Co-filed a non-binding resolution calling for clear Climate related targets and disclosure.  In addition, engaged with executive management on the topic

Q1 2021

Sanlam

A follow up engagement with the Chairman and CEO regarding related party transactions and worrying deterioration in governance standards

Q1 2021

Prosus

Engaged with the Prosus and Naspers remuneration committee regarding general governance, alignment with shareholders, quantum of pay and KPI’s

Q1 2021

Pepkor

Engaged with the company regarding the small related party transaction

Q1 2020

Oceana

Engaged with the CEO and Interim CFO on their proposed empowerment transaction

Q1 2021

Spar

Engaged with the Financial Director regarding the re-election of certain members to the Audit Committee

Q1 2021

Sanlam

Abax sent a letter to the Chairman of the Board recording our objection to Sanlam’s investment in ARC Financial Services Sub Co.

Q1 2021

Investec

Engagement with the Chairman and Chair of the Remuneration Committee regarding board succession, remuneration and other governance matters

Q1 2021

Mediclinic

Abax participated in the Mediclinic International 2021 Perception Study

Q1 2021

Mediclinic

Engaged with management regarding new remuneration structure and targets

Q1 2021

Sanlam

Abax participated in the Sanlam Corporate Reputation and Stakeholder Engagement Survey

Q4 2020

Coronation Fund Managers

Discussion regarding further disclosures made in the 2020 integrated report

Q4 2020

Naspers

Discussion with Chief People Officer regarding worrying associations of SA CEO

Q4 2020

Mediclinic

Review of revisions to remuneration policy

Q4 2020

Mr Price

Remuneration discussion, reviewing proposed new long term incentive structure